GSK PLC

GSK PLC tops Q4 earnings, driven by specialty HIV and respiratory drugs, aims for £40B sales by 2031, and plans strategic acquisitions to grow.

GSK cuts up to 350 R&D jobs yet boosts investment, showing its focus on oncology, immunology and rare‑disease breakthroughs amid portfolio gains and regulatory wins.

GSK’s $2.5 bn acquisition of Rapt Therapeutics gives the pharma giant a Phase IIb anti‑IgE allergy therapy, boosting its portfolio, opening high‑growth markets, and positioning it for value‑based reimbursement success.

GSK’s AI‑driven R&D and Summit Therapeutics oncology partnership aim to offset $2.1 bn in patent‑expiry losses, targeting a $950 m NPV if approvals arrive by 2027.

GSK’s new approvals for Exdensur and Nucala unlock a $27.9 billion‑plus Asian biologic market, boosting revenue, payer value‑based deals, and patient access in Japan and China.

GSK sells its U.S. manufacturing plant to Samsung Biologics for $280 million, boosting Samsung’s first U.S. site, strengthening supply‑chain resilience, and funding GSK’s R&D while it cuts respiratory drug prices for better patient access.

GSK’s new drug Exdensur (depemokimab) gets UK approval, proving it reduces asthma and nasal‑polyp symptoms by targeting IL‑5Rα with a twice‑yearly shot.

GSK’s latest EU and US approvals—depemokimab, Nucala, Arexvy, Blujepa—show how pricing, reimbursement and supply‑chain agility drive commercial success in respiratory and infectious disease markets.

GSK reaffirms a £30bn U.S. expansion, prioritising drug development and manufacturing to tap high‑revenue markets amid new zero‑duty trade terms.

GSK PLC is navigating market dynamics, reimbursement models, and operational challenges in the healthcare delivery sector, with strategic initiatives such as reviving the Leucovorin therapy and investing in digital transformation expected to drive s…